Escribe una PREreview

Increase in SARS-CoV-2 RBD-specific IgA and IgG Antibodies in Human Milk from Lactating Women Following the COVID-19 Booster Vaccination

por Andrea M. Henle

Publicada: 24 de febrero de 2022
Servidor: medRxiv
DOI: 10.1101/2022.02.23.22271414

The CDC recommended a booster dose of the Pfizer-BioNTech Comirnaty (BNT162b2) COVID-19 mRNA vaccine in September 2021 for high-risk individuals. Pregnant and high-risk lactating women were encouraged to receive the booster to obtain potential prolonged protection for themselves and their infants. This study investigated the ability of the booster vaccine to increase IgA and IgG antibodies specific to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein in human milk compared to levels pre-booster. We found a significant increase in both anti-RBD-specific IgA and IgG antibodies in human milk 1-2 weeks after the Pfizer-BioNTech booster and at the study endpoint (60 days post-booster). These results suggest the booster vaccination enhances SARS-CoV-2 specific immunity in human breast milk, which may be protective for infants.

Key Points

Abs to SARS-COV-2 RBD are detected in blood ≥60 days post-Pfizer-BioNTech booster.
Human milk Abs to SARS-COV-2 RBD are higher ≥60 days post-booster vs pre-booster.

Puedes escribir una PREreview de Increase in SARS-CoV-2 RBD-specific IgA and IgG Antibodies in Human Milk from Lactating Women Following the COVID-19 Booster Vaccination. Una PREreview es una revisión de un preprint y puede variar desde unas pocas oraciones hasta un extenso informe, similar a un informe de revisión por pares organizado por una revista.

Antes de comenzar

Te pediremos que inicies sesión con tu ORCID iD. Si no tienes un iD, puedes crear uno.